Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
From there, you can schedule a virtual or in-office visit with a licensed provider
In patients with type 2 diabetes (T2DM), an impaired insulin response to GLP-1 and GIP contributes to hyperglycemia
Globally, obesity rates are accelerating significantly, compelling the healthcare professionals to prescribe these drugs mainly for their certified efficacy in facilitating weight loss, particularly in diabetic patients
Pros of GLP-1s: Non-surgical option Can lead to 1520% body weight loss in clinical trials May improve blood sugar, cholesterol, and inflammation Weekly injections, often self-administered Cons of GLP-1s: Real-world weight loss may be lower than clinical trials (510%) Side effects include nausea, vomiting, fatigue, and gastroparesis High cost and limited insurance coverage Weight may return if medication is stopped What is weight loss surgery
Upon administration, gemigliptin binds to DPP-4 and inhibits the breakdown of the incretin hormones, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP)
